PEGylation enhances tumor targeting of plasmid DNA by an artificial cationized protein with repeated RGD sequences, PronectinS

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the Editor in Chief because of concerns about several of the figures. • In Figure 1, gels 1(C) and 1(D) are identical, and also identical to the gels in Figures 1(F) and 1(H) in reference [1]. • Figure 1(F) is identical to Figure 1(C) in reference [1]. • Figure 1(A) is identical to Figure 1(A) in reference [1]. • Figure 1(B) is identical to Figure 1(G) in reference [1]. Figures 6 (A), (B), (C) and (D) are identical to Figures 7 (A)(2), (B)(2), (B)(3) and (C)(3) in reference [2], and also identical to Figures 7 US(-)(3), US(+)(1), US(-)(4) and US(+)(4) in reference [3]. [1] Hosseinkhani H, Tabata Y In vitro gene expression by cationized derivatives of an artificial protein with repeated RGD sequences, Pronectin®. [http://doi:10.1016/S0168-3659(02)00412-1] Journal of Controlled Release 86 (2003) 169–182 [2] Hosseinkhani H, Aoyama T, Ogawa O, Tabata Y Tumor targeting of gene expression through metal-coordinated conjugation with dextran. [http://doi:10.1016/S0168-3659(02)00425-X] Journal of Controlled Release 88 (2003) 297–312 [3] Hosseinkhani H, Kushibiki T, Matsumoto K, Nakamura T, Tabata Y Enhanced suppression of tumor growth using a combination of NK4 plasmid DNA-PEG engrafted cationized dextran complex and ultrasound irradiation. [http://doi:10.1038/sj.cgt.7700918] Cancer Gene Therapy 13 (2006) 479–489